|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated whether BRAF and NRAS mutational testing could contribute to the diagnosis of dedifferentiated metastatic melanoma when immunostains are negative.
|
30315274 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Digital droplet PCR was used to quantify BRAF and NRAS mutations in the plasma of patients with metastatic melanoma treated with immunotherapy.
|
30393817 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we describe the first case of disseminated intravascular coagulation occurring in BRAF and NRAS-mutant metastatic melanoma, and systematically review the literature regarding disseminated intravascular coagulation in melanoma.
|
31095038 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Idylla™ platform is a valuable rapid molecular diagnosis tool to reduce the delay in BRAF and NRAS analyses-related treatment choices for patients with metastatic melanoma presenting with acute deterioration.
|
28660280 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAF<sup>WT</sup> NRAS<sup>WT</sup> metastatic melanoma.
|
28921907 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, overall survival and response to anti-PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab) therapy of 364 patients with metastatic melanoma were assessed comparing 236 NRAS-mutated patients with 128 NRAS wildtype patients.
|
29843107 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Testing for NRAS mutation at codon Q61 is of therapeutic, prognostic, and diagnostic importance for metastatic melanoma, thyroid carcinoma, and colorectal carcinoma.
|
26712868 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether measurements of circulating, cell-free, tumor-associated BRAF(mutant) and NRAS(mutant) DNA (ctDNA) have a higher sensitivity than LDH to detect metastatic disease prior to treatment initiation and upon disease progression we studied patients with unresectable stage IIIC/IV metastatic melanoma receiving treatment with BRAF inhibitor therapy or immune checkpoint blockade and at least 3 plasma samples obtained during their treatment course.
|
26440707 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
|
27151331 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We observed an increase in NRAS mutant allele percentage (NRAS-MA%) in the metastatic melanoma progression from 2 patients with melanomas harbouring a NRAS mutation (p.Q61K in case 1 and p.Q61R in case 2).
|
26990546 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NRAS (Q61R) IHC assay is reliable and specific for the evaluation of the Q61R mutation status in metastatic melanoma and may be an alternative to molecular biology in evaluation of metastatic melanoma in routine practice.
|
25659223 |
2015 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subsequently, we quantified ctDNA ((V600E)BRAF,(V600K)BRAF or (Q61H)NRAS) in 6 stage IV melanoma patients across several time points during their treatment course.
|
26095797 |
2015 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The determination of NRAS and BRAF mutation status is a major requirement in the treatment of patients with metastatic melanoma.
|
26204954 |
2015 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The American Joint Committee on Cancer stage at first diagnosis of metastatic melanoma (stage III versus IV) was significantly associated with OS (P < 0.001), BRAF or NRAS mutation status had no significant prognostic impact on clinical outcomes.
|
24276025 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF and NRAS mutation status does not influence survival in metastatic melanoma.
|
24918823 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MEK targeting in N-RAS mutated metastatic melanoma.
|
24588908 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The organization of protein-protein interaction networks was assessed via the transcriptomes of four independent studies of metastatic melanoma and related to clinical outcome and MAP-kinase pathway mutations (BRAF/NRAS).
|
23738911 |
2013 |
|
Metastatic melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
|
23673558 |
2013 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
|
23922205 |
2013 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
|
23855428 |
2013 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) mutations in patients with metastatic melanoma.
|
22180178 |
2012 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In all, 22 cutaneous melanocytic lesions that had either developed or considerably changed in morphology in 19 patients undergoing treatment with selective BRAF inhibitors for BRAF-mutant metastatic melanoma at seven international melanoma centers within clinical trials in 2010 and 2011 were analyzed for mutations in BRAF and NRAS genes and immunohistologically assessed for expression of various signal transduction molecules in comparison with 22 common nevi of 21 patients with no history of BRAF inhibitor treatment.
|
22614973 |
2012 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this work, we show that mutation of N-RAS or B-RAF, signature genetic lesions present in most MMs, potently induced the expression of cell-surface CD200, a repressor of DC function.
|
18008004 |
2007 |